Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis
Public ClinicalTrials.gov record NCT03680131. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Vehicle-Controlled, Sample Size Adaptive Design Study to Evaluate the Safety and Efficacy of Topically Applied EB01 Cream in Healthy Adult Volunteers and Adult Subjects with Moderate to Severe Chronic Allergic Contact Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and efficacy of EB01 Cream (0.2%, 1.0%, 2.0%) applied twice per day (BID) for the treatment of moderate to severe chronic allergic contact dermatitis (ACD). The purpose of the open label extension is to assess the long-term safety, tolerability, and efficacy of EB01 2.0% cream in subjects with moderate to severe chronic allergic contact dermatitis.
Study identification
- NCT ID
- NCT03680131
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 211 participants
Conditions and interventions
Conditions
Interventions
- EB01 Cream Placebo Drug
- EB01 Cream 0.2% Drug
- EB01 Cream 1.0% Drug
- EB01 Cream 2.0% Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 15, 2019 (Actual)
- Primary completion
- Sep 21, 2022 (Actual)
- Completion
- Jan 17, 2023 (Actual)
- Last update posted
- Nov 14, 2024
2019 – 2023
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ark Clinical Research | Long Beach | California | 90806 | — |
| Foxhall Dermatology | Washington D.C. | District of Columbia | 20016 | — |
| Gold Coast Dermatology | Delray Beach | Florida | 33446 | — |
| Miami Dade Medical Research Institute, LLC | Miami | Florida | 33176 | — |
| The Dermatology Centre of Indiana | Plainfield | Indiana | 46168 | — |
| Forefront Dermatology | Louisville | Kentucky | 40202 | — |
| The Dermatology Clinic | Baton Rouge | Louisiana | 70808 | — |
| Oakland Hills Dermatology P.C. | Auburn Hills | Michigan | 48326 | — |
| Associated Skin Care Specialists | Fridley | Minnesota | 55432 | — |
| JUVA Skin & Laser Center | New York | New York | 10022 | — |
| UNC Dermatology and Skin Cancer Center | Chapel Hill | North Carolina | 27516 | — |
| Bexly Dermatology | Bexley | Ohio | 43209 | — |
| Apex Clinical Research Center, LLC | Mayfield Heights | Ohio | 44124 | — |
| West Virginia Research Institute | Morgantown | West Virginia | 26505 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03680131, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 14, 2024 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03680131 live on ClinicalTrials.gov.